EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia

Wael Gamal iD, Melanie Mediavilla-Varela, Angimar Uriepero-Palma, Javier Pinilla-Ibarz, Eva Sahakian iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wael Gamal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Th17 Cells, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although preclinical investigations have shown notable efficacy in solid tumor models utilizing in vitro-differentiated Th17 cells for adoptive cell therapy (ACT), the potential benefits of this strategy in enhancing ACT efficacy in hematological malignancies, such as chronic lymphocytic leukemia (CLL), remain unexplored. CLL is a B-cell malignancy with a clinical challenge of increased resistance to targeted therapies. T-cell therapies, including chimeric antigen receptor (CAR) T cells, have demonstrated limited success in CLL, which is attributed to CLL-mediated T-cell dysfunction and skewing toward immunosuppressive phenotypes. Herein, we illustrate the feasibility of polarizing CD4+ T cells from the Eμ-TCL1 murine model, the most representative model for human CLL, into Th17 phenotype, employing a protocol of T-cell activation through the inducible co-stimulator (ICOS) alongside a polarizing cytokine mixture. We demonstrate augmented memory properties of in vitro-polarized IL-17-producing T cells, and preliminary in vivo persistence in leukemia-bearing mice. Our findings gain translational relevance through successful viral transduction of Eμ-TCL1 CD4+ T cells with a CD19-targeted CAR construct during in vitro Th17 polarization. Th17 CAR T cells exhibited remarkable persistence upon encountering antigen-expressing target cells. This study represents the first demonstration of the potential of in vitro-differentiated Th17 cells to enhance ACT efficacy in CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellTh17 CellsImmunotherapy, AdoptiveAnimalsMiceHumansLymphocyte ActivationReceptors, Chimeric AntigenCell DifferentiationDisease Models, Animal

Stichwörter der Autor:innen

CAR T cellCLLTh17adoptive cell therapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

ORCID-Profile: Wael Gamal, Eva Sahakian

Zitieren

APA

Gamal, W., Mediavilla-Varela, M., Uriepero-Palma, A., Pinilla-Ibarz, J., & Sahakian, E. (2024). Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126324

Vancouver

Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E. Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126324

BibTeX
@article{Gamal2024,
  author = {Gamal, Wael and Mediavilla-Varela, Melanie and Uriepero-Palma, Angimar and Pinilla-Ibarz, Javier and Sahakian, Eva},
  title = {Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126324}
}
Kostenlos starten →